Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study

FREE study group, Francesco Blasi, Vincenzo Carnovale, Giuseppe Cimino, Vincenzina Lucidi, Donatello Salvatore, Barbara Messore, Marta Bartezaghi, Elisa Muscianisi, Pasquale Alberto Porpiglia

Research output: Contribution to journalArticle

Abstract

Background: A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for treatment compliance; moreover, studies on treatment compliance with inhaled antibiotics are limited. This study assessed compliance to TOBI® Podhaler™ (TIP) treatment in CF patients with chronic Pseudomonas aeruginosa (Pa) infections in a real-world setting using the Italian Treatment Adherence CF Questionnaire (ITA-CFq). Methods: This longitudinal, multicentre, cohort study included 2 follow-up (FU) visits: FU-1 at 3-months±15-days from the baseline visit and FU-2 at the end of third TIP cycle (or 6-months after enrolment, whichever occurred first). The effect of TIP on quality-of-life (QoL) and treatment satisfaction were evaluated using Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Treatment Satisfaction Questionnaire for Medication (TSQM), respectively. Overall compliance to treatments was assessed using ITA-CFq. Results: Eighty-two patients (mean age, 24.8 ± 7.9 years), including 22 paediatric patients (age,
Original languageEnglish
Pages (from-to)88-94
Number of pages7
JournalRespiratory Medicine
Volume138
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Pseudomonas Infections
Tobramycin
Cystic Fibrosis
Powders
Pseudomonas aeruginosa
Inhalation
Therapeutics
Multicenter Studies
Cohort Studies
Quality of Life
Pediatrics
Anti-Bacterial Agents

Keywords

  • CFQ-R, Compliance, Cystic fibrosis, ITA-CFq, Pseudomonas aeruginosa, Quality of life, TIP, TOBI podhaler, TSQM

Cite this

Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. / group, FREE study; Blasi, Francesco; Carnovale, Vincenzo; Cimino, Giuseppe; Lucidi, Vincenzina; Salvatore, Donatello; Messore, Barbara; Bartezaghi, Marta; Muscianisi, Elisa; Porpiglia, Pasquale Alberto.

In: Respiratory Medicine, Vol. 138, 01.05.2018, p. 88-94.

Research output: Contribution to journalArticle

group, FREE study ; Blasi, Francesco ; Carnovale, Vincenzo ; Cimino, Giuseppe ; Lucidi, Vincenzina ; Salvatore, Donatello ; Messore, Barbara ; Bartezaghi, Marta ; Muscianisi, Elisa ; Porpiglia, Pasquale Alberto. / Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. In: Respiratory Medicine. 2018 ; Vol. 138. pp. 88-94.
@article{9bfe636312b349d0ba05b41d0cd24279,
title = "Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study",
abstract = "Background: A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for treatment compliance; moreover, studies on treatment compliance with inhaled antibiotics are limited. This study assessed compliance to TOBI{\circledR} Podhaler™ (TIP) treatment in CF patients with chronic Pseudomonas aeruginosa (Pa) infections in a real-world setting using the Italian Treatment Adherence CF Questionnaire (ITA-CFq). Methods: This longitudinal, multicentre, cohort study included 2 follow-up (FU) visits: FU-1 at 3-months±15-days from the baseline visit and FU-2 at the end of third TIP cycle (or 6-months after enrolment, whichever occurred first). The effect of TIP on quality-of-life (QoL) and treatment satisfaction were evaluated using Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Treatment Satisfaction Questionnaire for Medication (TSQM), respectively. Overall compliance to treatments was assessed using ITA-CFq. Results: Eighty-two patients (mean age, 24.8 ± 7.9 years), including 22 paediatric patients (age,",
keywords = "CFQ-R, Compliance, Cystic fibrosis, ITA-CFq, Pseudomonas aeruginosa, Quality of life, TIP, TOBI podhaler, TSQM",
author = "group, {FREE study} and Francesco Blasi and Vincenzo Carnovale and Giuseppe Cimino and Vincenzina Lucidi and Donatello Salvatore and Barbara Messore and Marta Bartezaghi and Elisa Muscianisi and Porpiglia, {Pasquale Alberto}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.rmed.2018.03.034",
language = "English",
volume = "138",
pages = "88--94",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study

AU - group, FREE study

AU - Blasi, Francesco

AU - Carnovale, Vincenzo

AU - Cimino, Giuseppe

AU - Lucidi, Vincenzina

AU - Salvatore, Donatello

AU - Messore, Barbara

AU - Bartezaghi, Marta

AU - Muscianisi, Elisa

AU - Porpiglia, Pasquale Alberto

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for treatment compliance; moreover, studies on treatment compliance with inhaled antibiotics are limited. This study assessed compliance to TOBI® Podhaler™ (TIP) treatment in CF patients with chronic Pseudomonas aeruginosa (Pa) infections in a real-world setting using the Italian Treatment Adherence CF Questionnaire (ITA-CFq). Methods: This longitudinal, multicentre, cohort study included 2 follow-up (FU) visits: FU-1 at 3-months±15-days from the baseline visit and FU-2 at the end of third TIP cycle (or 6-months after enrolment, whichever occurred first). The effect of TIP on quality-of-life (QoL) and treatment satisfaction were evaluated using Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Treatment Satisfaction Questionnaire for Medication (TSQM), respectively. Overall compliance to treatments was assessed using ITA-CFq. Results: Eighty-two patients (mean age, 24.8 ± 7.9 years), including 22 paediatric patients (age,

AB - Background: A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for treatment compliance; moreover, studies on treatment compliance with inhaled antibiotics are limited. This study assessed compliance to TOBI® Podhaler™ (TIP) treatment in CF patients with chronic Pseudomonas aeruginosa (Pa) infections in a real-world setting using the Italian Treatment Adherence CF Questionnaire (ITA-CFq). Methods: This longitudinal, multicentre, cohort study included 2 follow-up (FU) visits: FU-1 at 3-months±15-days from the baseline visit and FU-2 at the end of third TIP cycle (or 6-months after enrolment, whichever occurred first). The effect of TIP on quality-of-life (QoL) and treatment satisfaction were evaluated using Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Treatment Satisfaction Questionnaire for Medication (TSQM), respectively. Overall compliance to treatments was assessed using ITA-CFq. Results: Eighty-two patients (mean age, 24.8 ± 7.9 years), including 22 paediatric patients (age,

KW - CFQ-R, Compliance, Cystic fibrosis, ITA-CFq, Pseudomonas aeruginosa, Quality of life, TIP, TOBI podhaler, TSQM

U2 - 10.1016/j.rmed.2018.03.034

DO - 10.1016/j.rmed.2018.03.034

M3 - Article

VL - 138

SP - 88

EP - 94

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -